Acute and repeated administration of the selective 5-HT(2A) receptor antagonist M100907 significantly alters the activity of midbrain dopamine neurons: an in vivo electrophysiological study
- PMID: 11252021
- DOI: 10.1002/syn.1031
Acute and repeated administration of the selective 5-HT(2A) receptor antagonist M100907 significantly alters the activity of midbrain dopamine neurons: an in vivo electrophysiological study
Abstract
We examined the effect of the acute and repeated administration of M100907 (formerly MDL 100907), a selective 5-HT(2A) receptor antagonist, on spontaneously active dopamine (DA) neurons in the substantia nigra pars compacta (SNC) and ventral tegmental area (VTA) of rats. This was accomplished using in vivo, extracellular single unit recording. The i.v. administration of M100907 (0.01-0.64 mg/kg) did not significantly alter the basal firing rate or pattern of spontaneously active SNC and VTA DA neurons. A single injection of either 0.01 or 0.03 mg/kg i.p. of M100907 did not significantly alter the number of spontaneously active DA neurons in either the SNC or VTA areas. However, 0.1 mg/kg i.p. of M100907 significantly increased the number of spontaneously active SNC and VTA DA neurons compared to vehicle-treated animals. A single injection of all doses of M100907 significantly decreased the degree of bursting in VTA DA neurons, whereas the 0.1 mg/kg dose increased the degree of bursting in SNC DA neurons. The repeated administration (one injection per day for 21 days) of 0.03 and 0.1 mg/kg i.p. of M100907 produced a significant decrease in the number of spontaneously active SNC and VTA DA neurons compared to vehicle-treated animals. The repeated administration of M100907 did not significantly alter the firing pattern of VTA DA neurons but significantly altered the firing pattern of SNC DA neurons. The results of this study indicate that M100907 administration alters the activity of midbrain DA neurons in anesthetized rats.
Copyright 2001 Wiley-Liss, Inc.
Similar articles
-
Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: an in vivo extracellular single cell study.Synapse. 2002 Dec 1;46(3):129-39. doi: 10.1002/syn.10116. Synapse. 2002. PMID: 12325040
-
Effect of the acute and chronic administration of the selective 5-HT6 receptor antagonist SB-271046 on the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study.Synapse. 2004 Apr;52(1):20-8. doi: 10.1002/syn.20002. Synapse. 2004. PMID: 14755629
-
The acute and chronic administration of the 5-HT(2B/2C) receptor antagonist SB-200646A significantly alters the activity of spontaneously active midbrain dopamine neurons in the rat: An in vivo extracellular single cell study.Synapse. 2006 Jun 15;59(8):502-12. doi: 10.1002/syn.20263. Synapse. 2006. PMID: 16565966
-
The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking.Prog Brain Res. 2008;172:625-46. doi: 10.1016/S0079-6123(08)00929-1. Prog Brain Res. 2008. PMID: 18772053 Review.
-
Serotonin-dopamine interaction: electrophysiological evidence.Prog Brain Res. 2008;172:45-71. doi: 10.1016/S0079-6123(08)00903-5. Prog Brain Res. 2008. PMID: 18772027 Review.
Cited by
-
EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study.Psychopharmacology (Berl). 2004 Sep;175(3):382-8. doi: 10.1007/s00213-004-1817-7. Psychopharmacology (Berl). 2004. PMID: 15007535 Clinical Trial.
-
Time-dependent cross talk between spinal serotonin 5-HT2A receptor and mGluR1 subserves spinal hyperexcitability and neuropathic pain after nerve injury.J Neurosci. 2012 Sep 26;32(39):13568-81. doi: 10.1523/JNEUROSCI.1364-12.2012. J Neurosci. 2012. PMID: 23015446 Free PMC article.
-
Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors.Cereb Cortex. 2009 Jul;19(7):1678-86. doi: 10.1093/cercor/bhn204. Epub 2008 Nov 21. Cereb Cortex. 2009. PMID: 19029064 Free PMC article.
-
Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.Naunyn Schmiedebergs Arch Pharmacol. 2013 Feb;386(2):155-66. doi: 10.1007/s00210-012-0806-3. Epub 2012 Nov 6. Naunyn Schmiedebergs Arch Pharmacol. 2013. PMID: 23128852 Review.
-
Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors.Int J Neuropsychopharmacol. 2010 Nov;13(10):1299-314. doi: 10.1017/S146114571000009X. Epub 2010 Feb 17. Int J Neuropsychopharmacol. 2010. PMID: 20158933 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous